Endogenous Matrix-Derived Inhibitors of Angiogenesis

Pharmaceuticals

Malin Sund²  Pia Nyberg¹ 

[1] Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland; E-Mail:Department of Surgery, Umea University Hospital, Umea University, SE-90185 Umea, Sweden;

关键词: angiogenesis;    extracellular matrix;    collagen;    cancer;    therapy;    biomarker;   

DOI  :  10.3390/ph3103021

来源: mdpi

【 摘 要 】

Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM) surrounding cells. Many matrix-derived inhibitors of angiogenesis, such as endostatin, tumstatin, canstatin and arresten, are bioactive fragments of larger ECM molecules. These substances become released upon proteolysis of the ECM and the vascular basement membrane (VBM) by enzymes of the tumor microenvironment. Although the role of matrix-derived angiogenesis inhibitors is well studied in animal models of cancer, their role in human cancers is less established. In this review we discuss the current knowledge about these molecules and their potential use as cancer therapeutics and biomarkers.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.